Beyond Antibiotics: Developing the Potential of Microbiome-Based Treatments
- Presenting Phase 3 efficacy and safety data for MBK-01, a non-antibiotic therapy for Clostridioides difficile infection
- Exploring real-world evidence findings and insights from the compassionate use program
- Expanding clinical research efforts into new therapeutic areas for MBK-01